Are patients getting their GLP-1s for the lowest price possible?
The data will surprise you.

dosespot

GLP-1s by the Numbers

1 in 8 American adults have reported using a GLP-1, **40%** do so for weight loss[1]

70% of GLP-1s are issued through manufacturers, 30% through compounding pharmacies[2]

Medication adherence to GLP-1s is low – **46.3% at 180 days** and 32.3% at one year[3]

Fewer than **1 in 5 employer sponsored health plans** cover GLP-1s for weight loss[4]

A NEW DOSESPOT ANALYSIS FINDS THAT PATIENTS OVERPAID BY $10.2M FOR GLP-1s

- The data is representative of **102,166 GLP-1** prescriptions processed by DoseSpot in Q1 2025

- **92%** of prescriptions could have been filled at a lower cost regardless of insurance status (**96%** had some form of commercial insurance)

- Of the **$10.2M** in cumulative savings, **$7M** would have come from manufacturer cost-saving programs

- Insured patients still faced two barriers when it came to GLP access:
  1) they were on a plan that did not cover GLP-1s at all, or
  2) they were required to complete a prior authorization or step-therapy process to access coverage

Our analysis is grounded in patient-level claims data sourced from our de-identified, proprietary patient population. Starting with first-party NCPDP claim files, we layered in verified benefit information to calculate each patient's actual prescription cost and compare it to all applicable savings opportunities available in our current savings databases. For each case, we quantified the cost differential between patients who received no support and those who accessed available savings programs. We also calculated what the "loss" was for each patient that did not take advantage of the program. We extrapolated our findings using verified third-party data to estimate the broader impact across the eligible patient population.

Trends in GLP-1 Affordability & Access

- While recent quarters have shown improvements in formulary coverage and patient's understanding of avenues for lower cost alternatives, the vast majority of insured and uninsured patients are still unaware of cost saving programs.

- Due to recent regulatory changes, compounded GLP-1s are exiting the market, making affordability a critical component of GLP-1 medication adherence.

- Providers are unaware of these programs when prescribing GLP-1s, often leading the patient to search for information and leading to medication abandonment altogether.

- In recent months, some providers have begun partnering with pharma to offer direct to manufacturer programs raising concerns in regards to the sharing of patient data across entities.

1. KFF Health Tracking Poll May 2024: The Public's Use and Views of GLP-1 Drugs.
2. Becker's, 30% of GLP-1 medications acquired via compounding pharmacies, July 2024
3. JCMP. Real-world persistence and adherence to glucagon-like peptide-1 receptor agonists among obese commercially insured adults without diabetes. May 2024.
4. Health Affairs, Health Benefits In 2024: Higher Premiums Persist, Employer Strategies For GLP-1 Coverage And Family-Building Benefits, October 2024.

How does it work?

Patient Diagnosis & Treatment Decision

Our **real-time prescription benefit** access shows providers the patient's medication cost, co-pay, and available savings programs at the point of care. With clear cost information and savings opportunities, patients are more likely to pick up their prescription and adhere to the treatment plan.

A New Rx is Written

Integrated clinical decision support auto-populates patient data and provides alerts for drug interactions and dosage checks. These automated workflows reduce entry errors, leading to better care.

Checking Coverage & Sending the Rx

Electronic prior authorization in DoseSpot checks coverage details, reducing the time to prescribe.

Medication Adherence & Ongoing Support

DoseSpot's advanced reporting gives providers insight into Rx pickup rates - leading to timely follow-up, stronger adherence, and quicker refills.

Patient Connect

Patients automatically receive a complaint SMS with **links to co-pay savings, coupons, and pharmacy options**. The prescription is put in a holding queue for 20 minutes, while the patient coordinates care that's best for them. If no action is taken, the prescription will proceed to the initially selected pharmacy. Patient can opt out of communication at any time.

Reporting, Safety & Compliance

DoseSpot is Surescripts & Drummond certified for electronic prescription of controlled substances. Our dashboard capabilities provide insights into EPCS Audit and Incidents, PDMP/NARX reporting, HIPAA compliance, prescription reviews, and clinical operation and efficiency.

The Outcome?

Patients who engage with an organization using DoseSpot **save more money, get prescriptions faster, and adhere to treatment plans**. Healthcare providers streamline their ePrescribing operations, reducing medication errors and increasing medication adherence, ultimately increasing patient satisfaction.

Key Benefits

- Reduced administrative burden for providers and their staff by minimizing callbacks and treatment delays.

- An ePrescribing workflow that puts the patient first – driving patient satisfaction, medication adherence and retention.

- Patients select cost-saving programs and preferred pharmacies without back and forth with the prescriber.

- Workflow customization available for health technology vendors to control patient selection program based on NDCs.

Your provider wrote you a Rx today for Zep*****.

The manufacturer has provided a discount card for this medication. You may pay as little as $25.

BIN: 610020
PCN: PDMI
GRP: 74670008
ID: 19362828801

Add to wallet: https://eJilly/3EJUA9h

Reply STOP to opt out & HELP for help